FI953981A0 - 2-Bensyl-polycykliska guaninderivat och förfarande för deras framställning - Google Patents

2-Bensyl-polycykliska guaninderivat och förfarande för deras framställning

Info

Publication number
FI953981A0
FI953981A0 FI953981A FI953981A FI953981A0 FI 953981 A0 FI953981 A0 FI 953981A0 FI 953981 A FI953981 A FI 953981A FI 953981 A FI953981 A FI 953981A FI 953981 A0 FI953981 A0 FI 953981A0
Authority
FI
Finland
Prior art keywords
benzyl
preparation
guanine derivatives
polycyclic guanine
polycyclic
Prior art date
Application number
FI953981A
Other languages
English (en)
Finnish (fi)
Other versions
FI953981A (sv
Inventor
Deen Tulshian
Brian A Mckittrick
Yan Xia
Samuel Chackalamannil
Dinesh Gala
Donald J Dibenedetto
Max Kugelman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI953981A0 publication Critical patent/FI953981A0/sv
Publication of FI953981A publication Critical patent/FI953981A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
FI953981A 1993-02-26 1995-08-24 2-Bensyl-polycykliska guaninderivat och förfarande för deras framställning FI953981A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2459993A 1993-02-26 1993-02-26
US2354993A 1993-02-26 1993-02-26
PCT/US1994/001728 WO1994019351A1 (en) 1993-02-26 1994-02-24 2-benzyl-polycyclic guanine derivatives and process for preparing them

Publications (2)

Publication Number Publication Date
FI953981A0 true FI953981A0 (sv) 1995-08-24
FI953981A FI953981A (sv) 1995-08-24

Family

ID=26697306

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953981A FI953981A (sv) 1993-02-26 1995-08-24 2-Bensyl-polycykliska guaninderivat och förfarande för deras framställning

Country Status (14)

Country Link
US (1) US5939419A (sv)
EP (1) EP0686157A1 (sv)
JP (1) JPH08507068A (sv)
KR (1) KR960701058A (sv)
CN (1) CN1118600A (sv)
AU (1) AU681875B2 (sv)
CA (1) CA2156918A1 (sv)
FI (1) FI953981A (sv)
HU (1) HUT72640A (sv)
IL (1) IL108754A0 (sv)
NZ (1) NZ262797A (sv)
SG (1) SG43809A1 (sv)
TW (1) TW270118B (sv)
WO (1) WO1994019351A1 (sv)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
ZA969888B (en) * 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6403799B1 (en) * 1999-10-21 2002-06-11 Agouron Pharmaceuticals, Inc. Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
MXPA04001891A (es) * 2001-08-28 2004-06-15 Schering Corp Inhibidores policiclicos de guanina fosfodiesterasa v.
CA2459161A1 (en) * 2001-08-31 2003-03-13 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain
JP2005509038A (ja) * 2001-11-09 2005-04-07 シェーリング　コーポレイション 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
ES2284056T3 (es) * 2003-07-31 2007-11-01 Schering Corporation Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil.
CA2546248A1 (en) * 2003-11-21 2005-06-09 Schering Corporation Phosphodiesterase v inhibitor formulations
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
AU2006255028B2 (en) * 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
KR20080091452A (ko) 2005-12-23 2008-10-13 아스트라제네카 아베 위장 장애의 치료를 위한 이미다졸 유도체
CN101384558A (zh) 2005-12-23 2009-03-11 阿斯利康(瑞典)有限公司 Gaba-b受体调节剂
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20090042227A (ko) * 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP2010509399A (ja) 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
US7901872B2 (en) 2007-05-21 2011-03-08 Macronix International Co., Ltd. Exposure process and photomask set used therein
RU2010101611A (ru) * 2007-06-21 2011-07-27 Шеринг Корпорейшн (US) Полициклические производные гуанина и способы их применения
AU2008331833A1 (en) * 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
CN104402893A (zh) 2007-12-06 2015-03-11 武田药品工业株式会社 有机化合物
WO2009144548A1 (en) * 2008-05-28 2009-12-03 Glenmark Pharmaceuticals S.A. Imidazo [2,1-b] purine derivatives as trpa1 modulators
EP3031324A3 (en) 2008-06-10 2016-09-07 AbbVie Inc. Tricyclic kinase inhibitors
MX2011005936A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
WO2010065153A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
GEP20146030B (en) 2008-12-06 2014-02-10 Intracellular Therapies Inc Organic compounds
MX2011005933A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
SG171777A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
CA2740385A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc NEW REGULATOR PROTEINS AND HEMMER
CN102711470A (zh) 2009-12-01 2012-10-03 雅培制药有限公司 新的三环化合物
DK2506716T3 (en) 2009-12-01 2017-09-04 Abbvie Inc HIS UNKNOWN TRICYCLIC RELATIONS
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC COMPOUNDS
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
AU2014234990B2 (en) 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
JP2016518343A (ja) 2013-03-15 2016-06-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
ES2732442T3 (es) 2014-06-20 2019-11-22 Intra Cellular Therapies Inc Compuestos orgánicos
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
MX2017007377A (es) 2014-12-06 2017-11-06 Intra Cellular Therapies Inc Compuestos organicos.
KR20180081523A (ko) 2015-10-16 2018-07-16 애브비 인코포레이티드 (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드 및 이의 고체상 형태의 제조 방법
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
US10981916B2 (en) 2016-12-28 2021-04-20 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
US11434247B1 (en) 2017-11-27 2022-09-06 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
CH643260A5 (fr) * 1980-05-02 1984-05-30 Nestle Sa 1-allyl-3-butyl-8-methylxanthine, procede de preparation et utilisation dans un medicament.
US4663446A (en) * 1983-06-27 1987-05-05 Trustees Of The Univ. Of Massachusetts N2 (phenyl substituted) deoxy guanosine containing compounds
DE3324115A1 (de) * 1983-07-05 1985-01-17 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE3445299A1 (de) * 1984-12-12 1986-06-19 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2028235C (en) * 1989-10-20 1997-01-21 Fumio Suzuki Condensed purine derivatives
ZA914727B (en) * 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
DE4022314A1 (de) * 1990-07-13 1992-01-16 Boehringer Ingelheim Kg Verfahren zur herstellung von 2-chlor-1,7-dihydropurin-6-on und verfahren zu dessen reinigung
DE4035599A1 (de) * 1990-11-06 1992-05-07 Dresden Arzneimittel Neue 5-(phenoxyalkanoylamino)-uracile, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP3260037B2 (ja) * 1994-06-17 2002-02-25 松下電器産業株式会社 超音波ドプラ血流計

Also Published As

Publication number Publication date
US5939419A (en) 1999-08-17
AU6268794A (en) 1994-09-14
TW270118B (sv) 1996-02-11
IL108754A0 (en) 1994-06-24
HU9502464D0 (en) 1995-10-30
SG43809A1 (en) 1997-11-14
NZ262797A (en) 1997-08-22
AU681875B2 (en) 1997-09-11
CN1118600A (zh) 1996-03-13
JPH08507068A (ja) 1996-07-30
HUT72640A (en) 1996-05-28
KR960701058A (ko) 1996-02-24
WO1994019351A1 (en) 1994-09-01
FI953981A (sv) 1995-08-24
EP0686157A1 (en) 1995-12-13
CA2156918A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
FI953981A0 (sv) 2-Bensyl-polycykliska guaninderivat och förfarande för deras framställning
FI973426A0 (sv) Benzopyran innehållande föreningar och förfarande för deras framställning
FI941137A (sv) 2-debensoyl-2-acyltaxolderivat och förfaranden för framställning av dessa
FI961599A (sv) 1N-alkyl-N-arylpyrimidinaminer och derivat därav
PT92487A (pt) Processo para a preparacao de derivados de peptidos
DE69224006D1 (de) Kreppverfahren
BR9408463A (pt) Novos derivados de ginkgolide e processo para sua preparação
PT98638A (pt) Processo para a preparacao de derivados de borsolina
DK0719278T3 (da) Androstenonderivat
CY2005005I1 (el) Pyrrolidine derivatives
PT90748A (pt) Processo par a preparacao de 4-amino-3-carboxi-quinoleinas e - naftiridinas
PT89779A (pt) Processo para a preparacao de derivados da piperidina
FI944713A (sv) 4-difenylmetylpiperidinderivat och förfarande för deras framställning
PT89780A (pt) Processo para a preparacao de derivados da tetrahidroisoquinolina
PT89922A (pt) Processo para a preparacao de derivados da tiazolidenodiona
FI940769A (sv) Förfarande för framställning av 2-aminotiazolderivat
DE69402126D1 (de) Anthracenderivate
PT89545A (pt) Processo para a preparacao de derivados da isoquinolinona
EE03878B1 (et) 5-O-desosaminüül-6-O-metüülerütronoliid A derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete ühendite valmistamiseks
PT877738E (pt) Processo para a preparacao de derivados de fenil-imidazolidina
FI940775A0 (sv) Förfarande för framställning av alfa-fenylisoserinderivat och användning av dem
PT89775A (pt) Processo para a preparacao de derivados de isoquinolina
PT91027A (pt) Processo para a preparacao de derivados peptidicos
PT92539A (pt) Processo para a preparacao de derivados de anfotericina b
FI944842A (sv) Fluorerade 4-aminoandrostadienonderivat och förfarande för deras framställning

Legal Events

Date Code Title Description
FD Application lapsed